Biomedical Engineering Reference
In-Depth Information
67. Handrock R, Herzig S (1996) Stereoselectivity of Ca
2
รพ
channel block by dihydropyridines:
no modulation by the voltage protocol. Eur J Pharmacol 309:317-321
68. Rovnyak GC, Kimball SD, Beyer B, Cucinotta G, DiMarco JD, Gougoutas J, Hedberg A,
Malley M, McCarthy JP (1995) Calcium entry blockers and activators: conformational and
structural determinants of dihydropyrimidine calcium channel modulators. J Med Chem
38:119-129
69. Hemmateenejad B, Safarpour MA, Miri R, Taghavi F (2004) Application of
ab initio
theory
to QSAR study of 1,4-dihydropyridine-based calcium channel blockers using GA-MLR and
PC-GA-ANN procedures. J Comput Chem 25:1495-1503
70. Mahmoudian M, Richards WGA (1990) Quantum chemical study of structure-activity
relationships of dihydropyridine calcium antagonists. J Sci Technol IR Iran 1:261-265
71. Gaudio AC, Korolkovas A, Takahata Y (1994) Quantitative structure-activity relationships
for 1, 4 -dihydropyridine calcium channel antagonists (nifedipine analogues): a quantum
chemical/classical approach. J Pharm Sci 83:1110-1115
72. Berntsson P, Wold S (1986) Comparison between X-ray crystallographic data and physico-
chemical parameters with respect to their information about the calcium channel antagonist
activity of 4-phenyl-1,4-dihydropyridines. Quant Struct Act Relat 5:45-50
73. Hemmateenejad B, Miri R, Akhond M, Shamsipur M (2002) Quantitative structure-activity
relationship study of recently synthesized 1, 4-dihydropyridine calcium channel antagonists.
Application of the Hansch analysis method. Arch Pharm Weinheim 335:472-480
74. Gupta SP, Mathur AN, Nagappa AN, Kumar D, Kumaran S (2003) A quantitative structure-
activity relationship study on a novel class of calcium entry blockers:1-[{4-(aminoalkoxy)
phephenyl} sulphonyl] Indolizines. Eur J Med Chem 38:867-873
75. Miri R, Javidnia K, Hemmateenejad B, Tabarzad M, Jafarpour M (2009) Synthesis, evalua-
tion of pharmacological activities and quantitative structure-activity relationship studies of a
novel group of bis(4-nitroaryl-1,4-dihyropyridine). Chem Biol Drug Des 73:225-235
76. Hemmateenejad B, Miri R, Akhond M, Shamsipur M (2002) QSAR study of the calcium
channel antagonist activity of some recently synthesized dihydropyridine derivatives. An
application of genetic algorithm for variable selection in MLR and PLS methods.
Chemometr Intell Lab Syst 64:91-99
77. Hemmateenejad B, Akhond M, Miri R, Shamsipur M (2003) Genetic algorithm applied to
the selection of factors in principal component-artificial neural networks: application to
QSAR study of calcium channel antagonist activity of 1,4-dihydropyridines (nifedipine
analogous). J Chem Inf Comput Sci 43:1328-1334
78. Si HZ, Wang T, Zhang Ke Jun, De Hua Z, Fane Bo Tao (2006) QSAR study of 1,
4-dihydropyridine calcium channel antagonists based on gene expression programming.
Bioorg Med Chem 14:4834-4841
79. Safarpour MA, Hemmateenejad B, Miri R, Jamali M (2004) Quantum chemical-QSAR study
of some newly synthesized 1,4-dihydropyridine calcium channel blockers. QSAR Comb Sci
22:997-1005
80. Yao X, Liu H, Zhang R, Liu M, Hu Z (2005) QSAR and classification study of
1,4-dihydropyridine calcium channel antagonists based on least squares support vector
machines. Mol Pharm 2:348-356
81. Costa MCA, Gaudio AC, Takahata Y (1997) A comparative study of principal component
and linear multiple regression analysis in SAR and QSAR applied to 1,4-dihydropyridine
calcium channel antagonists (nifedipine analogues). J Mol Struct Theochem 394:291-300
82. Schleifer KJ, Tot E (2002) CoMFA, CoMSIA and GRID/GOLPE studies on calcium entry
blocking 1,4-dihydropyridines. Quant Struct Act Rel 21:239-248
83. Kawada T, Hsiao-Tung S, Nakazawa M, Imai S (2000) In vitro effects of the new calcium
antagonist lacidipine. Jpn J Pharmacol 62:289-296
84. Van Amsterdam FTM, Roveri A, Maiorino M, Ratti E, Ursini F (1992) Lacidipine: a
dihydropyridine calcium antagonist with antioxidant activity. Free Redic Biol Med
12:183-187
